



Letter to the Editor From Cuny et al: “Correlation of Preoperative Imaging Findings and Parathyroidectomy Outcomes Support NICE 2019 Guidance”

Thomas Cuny, Pauline Romanet, David Taieb, Frederic Sebag

► To cite this version:

Thomas Cuny, Pauline Romanet, David Taieb, Frederic Sebag. Letter to the Editor From Cuny et al: “Correlation of Preoperative Imaging Findings and Parathyroidectomy Outcomes Support NICE 2019 Guidance”. *Journal of Clinical Endocrinology and Metabolism*, 2022, 107 (6), pp.E2642-E2643. 10.1210/clinem/dgac123 . hal-03780223

HAL Id: hal-03780223

<https://amu.hal.science/hal-03780223>

Submitted on 27 Feb 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Letter to the Editor from Cuny, et al: “Correlation of pre-operative imaging findings and parathyroidectomy outcomes support NICE 2019 guidance”

Thomas Cuny¹, Pauline Romanet², David Taïeb³, Frédéric Sebag⁴

¹Aix Marseille Univ, APMH, Marseille Medical Genetics, Inserm U1251, Hôpital de la Conception, Service d'Endocrinologie, Marseille, France

²Aix Marseille Univ, APMH, Marseille Medical Genetics, Inserm U1251, Hôpital de la Conception, Laboratoire de Biologie moléculaire, Marseille, France

³Aix Marseille Univ, APMH, Hôpital de la Timone, Service de Médecine Nucléaire, Marseille, France

⁴Aix Marseille Univ, APMH, Hôpital de la Conception, Service de Chirurgie Endocrinienne, Marseille, France

Corresponding author and person to whom requests should be addressed:

Thomas Cuny, MD PhD, Service d'Endocrinologie, Hôpital de la Conception, APMH

147 Boulevard Baille, 13005 Marseille, France

Mail: thomas.cuny@ap-hm.fr

Word count: 453

Dear Editor,

We read with great interest the paper by Chander *et al.*, published in *The Journal of Clinical Endocrinology & Metabolism*, on the outcomes of patients following parathyroid surgery for primary hyperparathyroidism (pHPT) (1). Taking into account the value of preoperative imaging, the authors have distinguished three different scenarios: 1) those with concordance between parathyroid ultrasonography (US) and sestamibi scan for a single gland abnormality, 2) those with discordant findings between US and sestamibi scan and 3) those with both imaging studies negative, a condition recently reported as being associated with an increased risk of persistent disease following parathyroidectomy (2). The authors should be congratulated for achieving a 96% cure rate in this population, as we have done (3). They have also stated that surgery should be considered regardless of the pre-operative imaging findings, as recommended by the NICE guidelines (4). We would like to emphasize that, in this specific population, some critical information needs to be addressed to better understand both results and recommendations.

Persistent disease is defined as persistent pHPT in the six months following surgery (5); we thus consider that the criteria for “cure” used by the authors (i.e., normalization of calcium levels at two weeks post-operatively) is suboptimal and may underestimate persistent disease rate (5).

Negative imaging in pHPT is also associated with a higher prevalence of multiglandular disease (3), potentially indicative of multiple endocrine neoplasia type 1 (MEN1) or familial hypocalciuric hypercalcemia (FHH) (6). Recently, we have shown that FHH patients often show negative parathyroid imaging (6,7). As recommended, the authors used a calcium:creatinine clearance ratio (CCCR) > 0.01 to rule out FHH. However, taken alone, CCCR is of limited clinical value due to its reduced diagnostic sensitivity with up to 50% of

FHH patients with a CCCR > 0.01 (6,8). Therefore, we suggest further investigations for pHPT patients with negative imaging or in favor of multiglandular disease. For FHH, due to the high disease penetrance (> 90%), calcemia measurements in the first-degree relatives can document FHH and, ultimately, guide genetic testing (8). In this contextual knowledge, thorough informations regarding kindreds, the surgical strategy, number of resected glands, gross aspect of the resected glands, gland weight and, eventually, pathological results, are crucial to properly characterize the patient and offer the best management. Indeed, our experience taught us that FHH patients can have calcemia exceeding 2.8 mmol/l, and that familial forms of multiglandular disease like FHH, could be diagnosed in patients older than seventy years old (7).

Thus, with great respect, we recommend these adjustments to the therapeutic strategies for pHPT patients with negative imaging, who represent a specific population that needs to be referred to a tertiary care center to ensure the most adapted diagnosis and management.

Disclosure Statement: The authors have nothing to disclose.

References

1. **Chander NR, Chidambaram S, Van Den Heede K, DiMarco AN, Tolley NS, Palazzo FF.** Correlation of pre-operative imaging findings and parathyroidectomy outcomes support NICE 2019 guidance. *J. Clin. Endocrinol. Metab.* 2021. doi:10.1210/clinem/dgab740.
2. **Bergenfels A, van Slycke S, Makay Ö, Brunaud L.** European multicentre study on outcome of surgery for sporadic primary hyperparathyroidism. *Br. J. Surg.* 2020;108(6):675–683.
3. **Sebag F, Hubbard JGH, Maweja S, Misso C, Tardivet L, Henry J-F.** Negative preoperative localization studies are highly predictive of multiglandular disease in sporadic primary hyperparathyroidism. *Surgery* 2003;134(6):1038–41; discussion 1041-2.
4. **National Institute for Health and Care Excellence.** *Hyperparathyroidism (primary): diagnosis, assessment and initial management.*; 2019. Available at: <https://www.nice.org.uk/guidance/ng132>.
5. **Udelsman R.** Approach to the patient with persistent or recurrent primary hyperparathyroidism. *J. Clin. Endocrinol. Metab.* 2011;96(10):2950–8.
6. **Mouly C, Vargas-Poussou R, Lienhardt A, Silve C, Hureaux M, Magdelaine C, Buffet A, Grunenwald S, Kuhn J-M, Brue T, Reznik Y, Tabarin A, Martin-Coignard D, Haymann J-P, Tack I, Bennet A, Caron P, Linglart A, Vezzosi D, Reference Centre for Rare Diseases of Calcium, Phosphate Metabolism.** Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients. *Clin. Endocrinol. (Oxf).* 2020;93(3):248–260.
7. **Lasbleiz A, Paladino NC, Romanet P, Castinetti F, Cuny T, Sebag F, Taïeb D.** Familial hypocalciuric hypercalcemia: the challenge of diagnosis. *Endocrine* 2021. doi:10.1007/s12020-021-02909-5.
8. **Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, Hannan FM, Cetani F, Sikjær T, Formenti AM, Björnsdóttir S, Schalin-Jantti C, Belaya Z, Gibb FW, Lapauw B, Amrein K, Wicke C, Grasemann C, Krebs M, Ryhänen EM, Makay O, Minisola S, Gaujoux S, Bertocchio J-P, Hassan-Smith ZK, Linglart A, Winter EM, Kollmann M, Zmierzak H-G, Tsourdi E, Pilz S, Siggelkow H, Gittoes NJ, Marcocci C, Kamenicky P.** European Expert Consensus on

Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. *Eur. J. Endocrinol.* 2021. doi:10.1530/EJE-21-1044.